New drug for Colorectal Cancer
Phase III clinical trial study showed that Regorafenib is an experimental drug that improves survival rate of people with colorectal cancer.
Dr. Grothey stated:
"For many years, people suffering from metastatic colorectal cancer could not be treated by standard chemotherapies and doctors did not have effective drugs to treat them. This new medicine shows improvement in overall survival of colon cancer patients who have run out of treatment options."
Researchers tested regorafenib in a phase III, randomized, placebo-controlled trial, made simultaneously in the U. S., Europe, Japan, Australia and China. They looked at survival outcomes in 760 patients whose cancer had progressed despite on standard chemotherapy regimens. Regorafenib is a multi-kinase inhibitor, that characterized by slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways that are activated in tumors.
The researchers revealed that people with metastatic colon cancer who were treated with the drug showed a 29% increase in overall survival in comparison with those treated with placebo. The median length of survival for patients treated with the drug increased from 5 months to 6.5 months. In general, regorafenib reduced patients' risk of dying from cancer during the trial by 23%.
Comments
(0)